The company has chosen Boston, Massachusetts USA, as the location for the headquarters of Immunovia Inc, a wholly owned subsidiary of Immunovia AB.
This new site is designed to accommodate a CLIA accredited reference laboratory for the Eastern USA as well as facilities for commercialization, covering marketing, sales and customer support. A team have been recruited to carry out the US market introduction of Immunovia’s first test, IMMray PanCan-d, in the second half of 2018.
“The market introduction of IMMray PanCan-d, our blood based test for earlier detection of pancreas cancer, is the main focus for Immunovia. We have therefore chosen to establish our USA operations headquarters in Boston, which is the major biotech hub in the world. A very experienced laboratory team will be moving into Immunovia´s own reference laboratory that will cover Eastern USA, adding to our commercial group that will also be located at the Boston facilities. This East coast laboratory complements the existing collaboration we have with Knight Diagnostic Laboratories in Portland, serving Western USA,” said Mats Grahn, CEO Immunovia.